Proteins encoded by mutant genes in cancers can be processed and presented on tumor cell surface by human leukocyte antigen (HLA) molecules, and such mutant peptides are called Neoantigens. Neoantigens are naturally existing tumor markers. To identify the exact sequence of a neoantigen with high confidence is the key to the success of many cancer immunotherapeutics. In this presentation, we will discuss advancements and difficulties of prediction-dependent and prediction-independent neoantigen identification strategies. We will review the latest development of technologies for neoantigen identification and introduce our unique neoantigen detection and quantification pipeline based on a triple quadrupole mass spectrometer.

 

 

Learning Objectives: